Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

13.94USD
1:21pm EST
Change (% chg)

$-0.04 (-0.29%)
Prev Close
$13.98
Open
$14.00
Day's High
$14.31
Day's Low
$13.71
Volume
217,457
Avg. Vol
825,950
52-wk High
$22.79
52-wk Low
$4.68

EXAS.OQ

Chart for EXAS.OQ

About

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company's product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $1,631.57
Shares Outstanding(Mil.): 108.41
Dividend: --
Yield (%): --

Financials

  EXAS.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.72 -- --
ROI: -45.73 -1.09 14.95
ROE: -47.00 -2.39 16.29

BRIEF-Exact Sciences appoints Jeff Elliott as CFO

* Exact Sciences appoints Jeff Elliott chief financial officer Source text for Eikon: Further company coverage:

Nov 08 2016

BRIEF-Exact Sciences Q3 loss per share $0.36

* Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S

Oct 26 2016

BRIEF-David Shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing

* David shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing Source text for Eikon: Further company coverage:

Aug 25 2016

BRIEF-D. E. Shaw & Co reports 5 pct passive stake in Exact Sciences as of July 22 - SEC Filing

* D. E. Shaw & Co reports 5 pct passive stake in Exact Sciences as of July 22 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 01 2016

BRIEF-Exact Sciences announces offering of 8.5 mln common stock

* Selling 8.5 million shares of common stock through underwriters at a public offering price of $15.50 per share

Jul 28 2016

BRIEF-Exact Sciences files for potential mixed shelf - SEC filing

* Files for potential mixed shelf - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 27 2016

BRIEF-Exact Sciences posts Q2 loss per share of $0.46

* Generated revenues of $21.2 million during Q2 ended June 30, 2016, representing a 161-percent increase from $8.1 million in Q2 of 2015

Jul 26 2016

BRIEF-Exact Sciences'Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations

* Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations

Jun 15 2016

BRIEF-Exact Sciences statement regarding pending USPSTF colorectal cancer screening guidelines

* Exact Sciences statement regarding pending USPSTF colorectal cancer screening guidelines

Jun 15 2016

Competitors

  Price Chg
Quest Diagnostics Inc (DGX.N) $88.32 +0.32
Epigenomics AG (ECXn.F) €4.56 +0.03
GeneNews Ltd (GEN.TO) $0.40 +0.05

Earnings vs. Estimates